Nyeri Neuropati: Tantangan dan Perkembangan dalam Manajemen Berbasis Bukti

Raymond R Tjandrawinata

doi:10.56951/fqbssh75

Nyeri Neuropati: Tantangan dan Perkembangan dalam Manajemen Berbasis Bukti

Penulis

Raymond R Tjandrawinata Molecular Pharmacologist, Dexa Group

DOI:

https://doi.org/10.56951/fqbssh75

Editorial

Nyeri neuropati merupakan kondisi kronis akibat disfungsi sistem saraf somatosensori yang memerlukan pendekatan terapi multimodal untuk mengoptimalkan manajemen nyeri. Pregabalin, sebagai agen farmakoterapi utama, bekerja dengan menurunkan eksitabilitas neuron melalui modulasi kanal kalsium tipe alfa-2-delta, menunjukkan efektivitas dalam mengurangi gejala nyeri neuropati dengan profil farmakokinetik yang lebih unggul dibandingkan gabapentin. Pendekatan nonfarmakologis, seperti cognitive behavioral therapy (CBT) dan stimulasi listrik noninvasif, juga berperan dalam meningkatkan kualitas hidup pasien. Dengan berkembangnya penelitian terhadap agen terapi baru seperti cannabinoid dan mirogabalin, serta pendekatan berbasis personalisasi, strategi manajemen nyeri neuropati terus mengalami inovasi untuk meningkatkan efektivitas dan tolerabilitas terapi.

Unduhan

Baca Selengkapnya

Referensi

1. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.doi:10.1038/nrdp.2017.2.

2. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73. doi:10.1016/S1474-4422(14)70251-0.

3. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19. doi:10.1016/S1474-4422(10)70143-5.

4. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152(10):2204-5. doi:10.1016/j.pain.2011.06.017.

5. Bouhassira D, Attal N. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? Pain. 2019;160(Suppl1):S57-63. doi:10.1097/j.pain.0000000000001480.

6. Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154(11):2249-61. doi:10.1016/j.pain.2013.06.004.

7. Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 2018;17(5):456-66. doi:10.1016/S1474-4422(18)30071-1.

8. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. NeuroImage. 2007;37(Suppl 1):S80-8.doi:10.1016/j.neuroimage.2007.03.054.

9. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. doi:10.1002/14651858.CD007938.pub4.

10. Johnson MI, Bjordal JM. Transcutaneous electrical nerve stimulation for the management of painful conditions: focus on neuropathic pain. Expert Rev Neurother. 2011;11(5):735-53. doi:10.1586/ern.11.48.

11. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc.2015;90(4):532-45. doi:10.1016/j.mayocp.2015.01.018.

12. Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014;69(2):153-66. doi:10.1037/a0035747.

13. Thorn BE. Cognitive therapy for chronic pain: a step-by-step guide. New York: Guilford Publications; 2017.

14. Zeidan F, Vago DR. Mindfulness meditation-based pain relief: a mechanistic account. Ann N Y Acad Sci. 2016;1373(1):114-27. doi:10.1111/nyas.13153.

15. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4(4):e0022. doi:10.5041/RMMJ.10129.

16. Kremer M, Salvat E, Muller A, et al. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. 2016;338:183-206. doi:10.1016/j.neuroscience.2016.06.057.

17. Dominguez E, Rivat C, Pommier B, et al. JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem.

2008;107(1):50-60. doi:10.1111/j.1471-4159.2008.05566.x.

18. Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156(Suppl1):S104-14. doi:10.1097/01.j.pain.0000460358.01998.15.

19. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-51. doi:10.1016/j.pain.2007.08.033.

20. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19. doi:10.1016/S1474-4422(10)70143-5.